



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On August 24, 2015, the board of directors (the "Board") of Nemus Bioscience, Inc. (the "Company") terminated the employment of John B. Hollister as the Company's Chief Executive Officer and he will no longer serve as an employee, officer or director of the Board, effective immediately. Mr. Hollister ending his tenure on the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices, or other occurrence that would require disclosure under Item 5.02(a) of Form 8-K. A copy of Mr. Hollister's letter is filed as Exhibit 17.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On August 24, 2015, the Board appointed Dr. Brian S. Murphy, 57, the Company's Chief Medical Officer, to serve as its new Chief Executive Officer and as a member of the Board to fill the vacancy created.

Dr. Murphy was appointed as the Company's Chief Medical Officer in October 2014. Dr. Murphy was the Chief Medical Officer of Nemus, the Company's subsidiary, from August 2014 to October 2014. From 2009 to August 2014, Dr. Murphy served as the Chief Medical Officer of Eiger Biopharmaceuticals. From 2003 to 2006, Dr. Murphy was Chief Medical Officer at Epiphany Biosciences. From 2003 to 2006, Dr. Murphy was Chief Medical Officer at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). From 2000 to 2002, Dr. Murphy was Medical Director of North America for Antivirals/Interferons/Transplant at Hoffmann-LaRoche. Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Program at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. Dr. Murphy is board-certified in internal medicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. Dr. Murphy completed parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical Epidemiology at the Massachusetts General Hospital and the other in Medical Ethics addressing issues of distributive justice and access to care at Brigham & Women's Hospital. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

Dr. Murphy has no family relationships with any director or executive officer of the Company, and there are no agreements or understandings between Dr. Murphy and any other person pursuant to which he was appointed to the Board. There are no related party transactions between the Company and Dr. Murphy that would require disclosure under Item 404(a) of Regulation S-K under the Securities Act of 1933, as amended. Dr. Murphy will serve as a director until the next annual meeting of the shareholders of the Company, or until his respective successor is duly elected and qualified or until his earlier death, disqualification, resignation or removal. No new compensatory arrangements were entered into with Dr. Murphy in connection with his appointment as the Company's new Chief Executive Officer.

**Item 7.01 Regulation FD Disclosure.**

On August 25, 2015, the Company issued a press release announcing the appointment of Dr. Murphy as Chief Executive Officer. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The Company is furnishing the information in this Current Report on Form 8-K and in Exhibit 99.1 to comply with Regulation FD. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statement and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
17.1	<a href="#">Letter dated August 24, 2015, from John B. Hollister</a>
99.1	<a href="#">Press release dated August 25, 2015</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Nemus Bioscience, Inc.**

Date: August 25, 2015

By: /s/ Elizabeth Berecz  
Elizabeth Berecz  
Chief Financial Officer

August 24, 2015

Nemus Bioscience, Inc.  
650 Town Center Drive, Suite 1770  
Costa Mesa, CA 92626  
Attn: Board of Directors

Effectively immediately today and in connection with the ending of my employment as Chief Executive Officer, I no longer serve as a member of the Board of Directors of Nemus Bioscience, Inc. and Nemus.

/s/ John B. Hollister  
John B. Hollister



## **NEMUS Bioscience Appoints Dr. Brian Murphy as CEO**

Costa Mesa, CA – August 25, 2015 – NEMUS Bioscience, Inc. (OTCQB: NMUS). The NEMUS Board of Directors has elected to promote Dr. Brian S. Murphy to serve as its Chief Executive Officer (CEO) of the Company effective immediately. Dr. Murphy has served as the Chief Medical Officer (CMO) of NEMUS since his hiring, a title he will retain, leading all research projects associated with the development of cannabinoid-based therapies for conditions of urgent medical need, including glaucoma and methicillin-resistant staphylococcus aureus (MRSA).

Prior to NEMUS, Dr. Murphy served in the CMO role at both publically traded and privately held companies, including Eiger Biosciences and Epiphany Biosciences both in the San Francisco Bay area, as well as CMO at Valeant Pharmaceuticals International, a \$76 billion market capitalization NYSE company. At Valeant, Dr. Murphy oversaw development projects in dermatology, neurology, infectious disease, and management of chemotherapy-related adverse events with the medication Cesamet (nabilone), one of only two FDA-approved synthetic cannabinoids. In addition to clinical and development roles, Dr. Murphy has also directed medical affairs where he interfaced with both the investment community as well as patient advocacy groups. At the start of his career in industry, Dr. Murphy served as Medical Director of North America for antivirals and transplant medicine at Roche (a \$41 billion market capitalization publicly-traded company) followed by working in clinical capacities and as Vice President for Marketing and Commercial Strategy for Hepatology at InterMune, Inc. which was acquired by Roche Holdings in 2014.

“We are extremely pleased to have Dr. Murphy as our CEO at NEMUS,” stated Cosmas N. Lykos, Co-Founder and Executive Chairman of the Board of NEMUS. “Dr. Murphy has a diverse background in the biotech industry spanning almost two decades. He also benefits from having senior management experience in start-ups as well as multi-national publicly-traded pharmaceutical companies like Roche and Valeant. We believe that his drug development expertise, especially related to cannabinoids like Cesamet at Valeant and experience with infectious diseases at Roche, coupled with working in investor and regulatory relations, make him the ideal leader for NEMUS,” Mr. Lykos stated.

“It is an honor to serve in this capacity at NEMUS, especially as cannabinoid-based medicines are on the verge of transforming the practice of medicine across a spectrum of disease indications. This company, through its relationship with our research collaborator, the University of Mississippi, has enormous potential to impact medical practice and therapeutics,” reported Dr. Murphy.

Dr. Murphy completed undergraduate studies at New York University and received a doctoral degree in medicine and masters degrees in public health and pharmacology from New York Medical College. He went on to complete a residency in internal medicine at Tufts-New England Medical Center in Boston and Chief Medical Resident in the Boston University training program. He completed parallel fellowships in internal medicine/clinical epidemiology at Massachusetts General Hospital and medical ethics at Brigham & Women’s Hospital, both institutions in the Harvard Medical School faculty program. Dr. Murphy also earned a master of public health (MPH) degree in health policy and management from the Harvard University School of Public Health and a master of business administration (MBA) from the Columbia University Graduate School of Business. He has also served as a reviewer for a number of medical journals, including the Annals of Internal Medicine and The Lancet. He is board certified in internal medicine and a member of Alpha Omega Alpha (AOA), the national honor medical society.

---

**ABOUT NEMUS BIOSCIENCE, INC.**

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. For more information, visit [www.nemusbioscience.com](http://www.nemusbioscience.com).

**FORWARD LOOKING STATEMENTS**

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.

**Contact:**

Investor Relations  
Mike Cole  
Vice President - MZ North America  
Main: 949-259-4988  
Mobile: 949-444-1341  
[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)  
[www.mzgroup.us](http://www.mzgroup.us)